Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven.
The company incurs virtually no additional costs for the onboarding and maintenance of new customers, except for COGS and associated production costs, which represent a relatively low cost of goods, generating a healthy margin for the Company. Because our cost and business structure for the Products Division is largely fixed, each new customer has a substantial financial impact and contribution to the bottom line.
“As promised, we continue to convert our pipeline of potentials into actual signed customers, adding to the building blocks of recurring revenue, with each customer helping to reduce our cash burn, and bringing us closer to our breakeven goals,” said Ilan Danieli, Precipio’s CEO. “Shareholders can expect more of these customers joining the ranks of our HemeScreen family, as we continue to support our customers in providing better patient care and improved economics through our proprietary technologies.”
